Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
- Status
- WITHDRAWN
- Phase
- NA
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
- Status
- COMPLETED
- Phase
- PHASE2
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2